Candel Aims High In Next Stage Of Cancer Immunotherapy Mission

Emerging Company Profile: Candel Therapeutics, formerly known as Advantagene, has hired a new leadership team and is aiming for a Phase III data read-out in prostate cancer in 2023.    

Dr. Paul-Peter Tak
Paul Peter Tak

The prostate cancer vaccine pipeline is littered with casualties – from the commercial failure of Dendreon Corporation’s approved Provenge (sipuleucel-T) to the late-stage clinical failure of Bavarian Nordic A/S’s Prostvac (rilimogene galvacirepvec) monotherapy and CureVac BV’s mRNA-based CV9104. And time and again, while cancer vaccines across a range of tumor types have shown promise in stimulating an immune response, they have subsequently failed to show clinical improvement in key endpoints that matter to patients, like overall survival.

Nevertheless, an immense investment in immunotherapy R&D, particularly in oncology, continues to support a populous ecosystem of cancer vaccine developers

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Emerging Company Profiles

More from Start-Ups & SMEs